Spotnitz W D
Department of Surgery, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
Thromb Haemost. 1995 Jul;74(1):482-5.
Fibrin sealant use in the United States has been limited because of the lack of a commercially available, government approved product. However, the significant need and usefulness of this material at the time of surgical operations has stimulated alternative sources of production. At the University of Virginia, the Blood Bank produces concentrated single donor or autologous fibrinogen for use with commercially available bovine thrombin in order to make fibrin sealant. The hemostatic and adhesive properties of fibrin sealant have been used since 1985 at this Center in a wide variety of operations with over 90% effectiveness. This chapter will review the development and role of this material in modern clinical surgery at this institution. The advantages, disadvantages, and never applications of this substance in various forms will be assessed. The role of fibrin sealant is increasing in this country and additional developmental work is continuing. The era of a commercially available product in the United States appears to be on the horizon.
在美国,由于缺乏可商业获取且经政府批准的产品,纤维蛋白密封剂的使用受到限制。然而,这种材料在外科手术时的巨大需求和实用性促使了其他生产来源的出现。在弗吉尼亚大学,血库生产浓缩的单供体或自体纤维蛋白原,与市售的牛凝血酶一起用于制备纤维蛋白密封剂。自1985年以来,该中心已在多种手术中使用纤维蛋白密封剂的止血和黏合特性,有效率超过90%。本章将回顾这种材料在该机构现代临床手术中的发展和作用。将评估这种物质各种形式的优缺点及新应用。纤维蛋白密封剂在该国的作用正在增加,更多的研发工作仍在继续。在美国,可商业获取产品的时代似乎即将到来。